Eiko Lifesciences Limited

As of June 30, 2026, Eiko Lifesciences Limited carries a market capitalization of 724.95M, placing it among publicly traded companies globally. Its enterprise value stands at 724.95M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Eiko Lifesciences Limited has 14.37M shares outstanding.

As of June 30, 2026, Eiko Lifesciences Limited trades at a trailing price-to-earnings ratio of 14.40.

As of June 30, 2026, Eiko Lifesciences Limited trades at an EV/EBITDA multiple of 9.22 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 1.23 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 10.59 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 724.95M versus a market cap of 724.95M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Eiko Lifesciences Limited recorded 19.16M in income tax expense. That works out to an effective tax rate of 25.11, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 76.32M, leaving 48.90M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 23, 2026, Eiko Lifesciences Limited's stock has declined approximately 0.66% over the past 52 weeks. The 50-day moving average sits at 47.92, while the 200-day moving average is 50.33.

Over the twelve months ended June 30, 2026, Eiko Lifesciences Limited generated 587.44M in revenue and converted that into 48.90M in net income, yielding earnings per share of 3.82. EBITDA reached 78.64M, while operating income came in at 68.48M.

Over the twelve months ended June 30, 2026, Eiko Lifesciences Limited posted a gross margin of 20.81, reflecting its pricing power and cost economics. The operating margin of 11.66 and net profit margin of 8.32 provide insight into operational efficiency.

Eiko Lifesciences Limited's most recent stock split took place on July 7, 2023 with a 13:15 split ratio.